This product is a blood volume expander. After intravenous injection, it can increase plasma colloidal osmotic pressure, absorb extravascular water into the systemic circulation to increase blood volume, and increase and maintain blood pressure. Its blood volume expansion effect is weaker and shorter than that of dextran 70, but its effect on improving microcirculation is stronger than that of dextran 70. It can disaggregate aggregated red blood cells and platelets, reduce blood viscosity, improve microcirculation, and prevent thrombosis. In addition, it also has an osmotic diuretic effect.

This product is a blood volume expander. After intravenous injection, it can increase plasma colloidal osmotic pressure, absorb extravascular water into the systemic circulation to increase blood volume, and increase and maintain blood pressure. Its blood volume expansion effect is weaker and shorter than that of dextran 70, but its effect on improving microcirculation is stronger than that of dextran 70. It can disaggregate already aggregated red blood cells and platelets, reduce blood viscosity, improve microcirculation, and prevent thrombosis. In addition, it also has an osmotic diuretic effect. This product has strong antigenicity. Since there are bacteria that produce this product in the normal intestine, some patients will have allergic reactions even after the first injection of this product. Mainly skin and mucous membrane allergic reactions.

It has a direct inhibitory effect on respiratory syncytial virus (RSV) and a direct inactivation effect on influenza virus A1 and A3. It has no local irritation and hemolysis in vivo. The LD50 of intravenous injection in mice is 122.14±41.44mg/kg; the LD50 of oral gavage in mice is 147.0g/kg; the LD50 of intramuscular injection is 55g/kg; the maximum tolerance and minimum lethal dose in mice are 48 and 49g/kg respectively. No accumulation effect is observed after six consecutive days of medication.

It can effectively reduce intracranial pressure and intraocular pressure, especially the intracranial pressure.

It can effectively reduce intracranial pressure and intraocular pressure, especially the intracranial pressure.

This product has a broad-spectrum antibacterial effect and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, and Gram-negative bacteria such as Haemophilus influenzae, Legionella pneumophila, and Neisseria gonorrhoeae. It also has antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and Mycoplasma pneumoniae and Chlamydia pneumoniae, but has poor effects on anaerobic bacteria and enterococci. Its mechanism of action is to inhibit the activity of bacterial DNA gyrase, prevent the synthesis and replication of bacterial DNA, and cause bacterial death.

This product is a new type of non-narcotic analgesic, with mild antipyretic and muscle relaxant effects. It is effective for moderate and severe pain. An intramuscular injection of 20 mg of this product is equivalent to the effect of 12 mg of morphine. It has a mild respiratory depressant effect. It has no depressant effect on the circulatory system. There is no tolerance and dependence.